Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-30 18:16:29 - browse：96262

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： When waiting feels immoral: Empathy in the emergency department

WSS

Alnylam reports growth in sales of rare disease treatments

FDA scientists endorse Pfizer/BioNTech Covid

Study suggests new cause of Down syndrome: cells linked to aging

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Allen Institute goes after foundational questions, CEO Costa says

Florida officials tell state schools to teach AP Psychology 'in its entirety'

knowledge

Wikipedia

focus

Continuity nursing helped my family in our darkest PICU moments

Medicare Advantage overpayments discussion gets experts fired up

State Dept. review finds Biden bears some blame for Afghanistan failures

Study suggests new cause of Down syndrome: cells linked to aging

Peter Hotez and the public health issue of online harassment

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Dobbs anniversary: the lost opportunity of abortion as health care

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Medicare proposal to cover medical devices draws a mixed reaction

Gene therapy denied for Afghan refugee whose father aided U.S.

explore

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Nonprofit, backed by Microsoft, to certify AI tools in health care

How to ethically and practically extend health care to all

At JPM 2024, hospital systems pitch financial strength to investors

FDA scientists endorse Pfizer/BioNTech Covid

Male doctors called my cancer incurable. A female doctor showed it wasn't

Wikipedia

focus

hotspot

entertainment